M2698 (MSC-2363318A) is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a targeted therapy for certain types of cancers, particularly those driven by specific genetic mutations or signaling pathways. Researchers are exploring its ability to inhibit key proteins or enzymes involved in cancer cell proliferation and survival, which could make it a promising candidate for personalized cancer treatment. Additionally, preclinical studies are assessing its efficacy in combination with other anticancer agents to enhance therapeutic outcomes and overcome drug resistance. Its development highlights its potential role in advancing precision medicine for cancer patients.